Embryonic Stem Cell Transcription Factor Signatures in the Diagnosis of Primary and Metastatic Germ Cell Tumors

The core embryonic stem cell transcription factors (TFs) OCT3/4 (OCT4), NANOG, and SOX2 have shared as well as nonoverlapping roles in stem cell growth and differentiation. These same TFs are also expressed in various types of human germ cell tumors (GCTs), implicating them in regulation of tumor growth and differentiation. Although NANOG and OCT3/4 are sensitive and specific markers for seminoma and embryonal carcinoma, neither factor aids in the clinically important distinction of seminomatous from nonseminomatous tumors. In contrast, expression profiling data suggest that SOX2 may help with this distinction. To determine if a panel of embryonic stem cell TFs (NANOG, OCT3/4, and SOX2) can facilitate the identification and distinction of seminomatous from nonseminomatous GCTs, we evaluated their expression by immunohistochemistry in primary testicular (n=41) and metastatic retroperitoneal (n=43) GCTs. Our results confirm NANOG and OCT3/4 as sensitive and specific markers for primary seminoma and embryonal carcinoma and demonstrate the novel finding that NANOG is a marker for metastatic GCTs. In addition, SOX2 is expressed in embryonal carcinoma but not pure seminoma and is therefore a useful diagnostic marker for distinguishing seminomatous and nonseminomatous GCTs. In summary, we find that the embryonic stem cell TF signature of seminoma is NANOG+, OCT3/4+, and SOX2−, whereas embryonal carcinoma is NANOG+, OCT3/4+, and SOX2+, and expect these immunohistochemical profiles will facilitate the diagnosis of both primary and metastatic GCTs.

[1]  K. Ligon,et al.  Comparative Analysis of Germ Cell Transcription Factors in CNS Germinoma Reveals Diagnostic Utility of NANOG , 2006, The American journal of surgical pathology.

[2]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[3]  Austin G Smith,et al.  Nanog promotes transfer of pluripotency after cell fusion , 2006, Nature.

[4]  Liang Cheng,et al.  Retroperitoneal Seminoma in Limited Biopsies: Morphologic Criteria and Immunohistochemical Findings in 30 Cases , 2006, The American journal of surgical pathology.

[5]  Megan F. Cole,et al.  Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.

[6]  X. Chen,et al.  The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells , 2006, Nature Genetics.

[7]  A. Olshen,et al.  Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. , 2006, Cancer research.

[8]  A. Hart,et al.  The pluripotency homeobox gene NANOG is expressed in human germ cell tumors , 2005, Cancer.

[9]  J. Richie Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. , 2005, The Journal of urology.

[10]  Megan F. Cole,et al.  Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells , 2005, Cell.

[11]  H. Leffers,et al.  Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours , 2005, Histopathology.

[12]  T. Tsukamoto,et al.  Sox2 expression in human stomach adenocarcinomas with gastric and gastric‐and‐intestinal‐mixed phenotypes , 2005, Histopathology.

[13]  Liang Cheng,et al.  OCT4 Immunohistochemistry Is Superior to Placental Alkaline Phosphatase (PLAP) in the Diagnosis of Central Nervous System Germinoma , 2005, The American journal of surgical pathology.

[14]  L. Olson,et al.  Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. , 2004, Carcinogenesis.

[15]  Pier Paolo Pandolfi,et al.  Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain , 2004, Development.

[16]  Liang Cheng,et al.  OCT4 Staining in Testicular Tumors: A Sensitive and Specific Marker for Seminoma and Embryonal Carcinoma , 2004, The American journal of surgical pathology.

[17]  Catherine L Nutt,et al.  The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas , 2004, Journal of neuropathology and experimental neurology.

[18]  Y. Eishi,et al.  Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. , 2004, International journal of oncology.

[19]  A. Marx,et al.  World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .

[20]  G. Reifenberger,et al.  Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas , 2004, Acta Neuropathologica.

[21]  P. Brown,et al.  Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Gown,et al.  CDX2, a Highly Sensitive and Specific Marker of Adenocarcinomas of Intestinal Origin: An Immunohistochemical Survey of 476 Primary and Metastatic Carcinomas , 2003, The American journal of surgical pathology.

[23]  Juan F. García,et al.  Analysis of Octamer-Binding Transcription Factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in Lymphomas , 2002, Modern Pathology.

[24]  E. Leteurtre,et al.  CD30 and CD117 (c-kit) Used in Combination Are Useful for Distinguishing Embryonal Carcinoma from Seminoma , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[25]  S. Tripp,et al.  Are Myogenin and MyoD1 Expression Specific for Rhabdomyosarcoma?: A Study of 150 Cases, With Emphasis on Spindle Cell Mimics , 2001, The American journal of surgical pathology.

[26]  S. Pileri,et al.  Expression of the CD30 antigen in non‐lymphoid tissues and cells , 2000, The Journal of pathology.

[27]  S. Suster,et al.  Germ cell tumors of the mediastinum and testis: a comparative immunohistochemical study of 120 cases. , 1999, Human pathology.

[28]  P. Hall,et al.  Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.

[29]  R. Motzer,et al.  Germ Cell Tumors , 2012 .

[30]  G. Mikuz,et al.  CD30 expression in seminoma. , 1996, Human pathology.

[31]  R. Lauro,et al.  Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[32]  L. Einhorn Treatment of testicular cancer: a new and improved model. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Wick,et al.  Placental-like alkaline phosphatase reactivity in human tumors: an immunohistochemical study of 520 cases. , 1987, Human pathology.

[34]  W. Hendry,et al.  Occult germ-cell testicular tumours. , 1983, British journal of urology.

[35]  K. Hirano,et al.  Immunoperoxidase study of alkaline phosphatase in testicular tumor , 1981, Cancer.